Which has higher valuation and earnings, DSGN or ABOS?

Design Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Design Therapeutics N/A N/A -$69.79M -$1.20 N/A Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A

Is DSGN or ABOS more profitable?

Design Therapeutics' return on equity of -33.07% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -33.07% -31.29% Acumen Pharmaceuticals N/A -123.07% -79.41%

Does the media favor DSGN or ABOS?

In the previous week, Design Therapeutics and Design Therapeutics both had 2 articles in the media. Acumen Pharmaceuticals' average media sentiment score of 1.87 beat Design Therapeutics' score of 0.94 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acumen Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation and earnings, ABOS or SLDB?

Solid Biosciences is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A Solid Biosciences N/A N/A -$174.32M -$1.95 N/A

Is ABOS or SLDB more profitable?

Solid Biosciences' return on equity of -73.42% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -123.07% -79.41% Solid Biosciences N/A -73.42% -61.13%

Does the media refer more to ABOS or SLDB?

In the previous week, Solid Biosciences had 2 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.87 beat Solid Biosciences' score of 0.72 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ABOS or CRMD?

In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 2 articles in the media. Acumen Pharmaceuticals' average media sentiment score of 1.87 beat CorMedix's score of 1.26 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CorMedix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ABOS or CLYM?

Climb Bio is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A Climb Bio N/A N/A -$59.85M -$0.78 N/A

Is ABOS or CLYM more profitable?

Climb Bio's return on equity of -31.45% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -123.07% -79.41% Climb Bio N/A -31.45% -30.39%

Does the media refer more to ABOS or CLYM?

In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 2 articles in the media. Acumen Pharmaceuticals' average media sentiment score of 1.87 equaled Climb Bio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Climb Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer ABOS or AVTE?

Acumen Pharmaceuticals presently has a consensus price target of $6.67, indicating a potential upside of 191.12%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Acumen Pharmaceuticals is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acumen Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, ABOS or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is ABOS or AVTE more profitable?

Aerovate Therapeutics' return on equity of -90.19% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -123.07% -79.41% Aerovate Therapeutics N/A -90.19% -77.47%

Acumen Pharmaceuticals (ABOS) Competitors

$2.29 -0.08 (-3.38%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$2.31 +0.02 (+0.87%)

As of 06/3/2026 07:51 PM Eastern

Compare

ABOS vs. DSGN, SLDB, CRMD, CLYM, and AVTE

Should you buy Acumen Pharmaceuticals stock or one of its competitors? MarketBeat compares Acumen Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acumen Pharmaceuticals include Design Therapeutics (DSGN), Solid Biosciences (SLDB), CorMedix (CRMD), Climb Bio (CLYM), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry.

How does Acumen Pharmaceuticals compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

Design Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

Design Therapeutics currently has a consensus target price of $16.50, indicating a potential upside of 58.05%. Acumen Pharmaceuticals has a consensus target price of $6.67, indicating a potential upside of 191.12%. Given Acumen Pharmaceuticals' higher probable upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Design Therapeutics' return on equity of -33.07% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Design Therapeutics has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Design Therapeutics and Design Therapeutics both had 2 articles in the media. Acumen Pharmaceuticals' average media sentiment score of 1.87 beat Design Therapeutics' score of 0.94 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Design Therapeutics beats Acumen Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Solid Biosciences?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Acumen Pharmaceuticals has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market.

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 10.2% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Solid Biosciences' return on equity of -73.42% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Solid Biosciences	N/A	-73.42%	-61.13%

Acumen Pharmaceuticals currently has a consensus target price of $6.67, suggesting a potential upside of 191.12%. Solid Biosciences has a consensus target price of $16.82, suggesting a potential upside of 145.52%. Given Acumen Pharmaceuticals' higher probable upside, equities research analysts clearly believe Acumen Pharmaceuticals is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Solid Biosciences is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

In the previous week, Solid Biosciences had 2 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.87 beat Solid Biosciences' score of 0.72 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Solid Biosciences beats Acumen Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to CorMedix?

Acumen Pharmaceuticals (NASDAQ:ABOS) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 2 articles in the media. Acumen Pharmaceuticals' average media sentiment score of 1.87 beat CorMedix's score of 1.26 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CorMedix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Acumen Pharmaceuticals presently has a consensus price target of $6.67, suggesting a potential upside of 191.12%. CorMedix has a consensus price target of $15.00, suggesting a potential upside of 82.26%. Given Acumen Pharmaceuticals' higher possible upside, equities research analysts clearly believe Acumen Pharmaceuticals is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

CorMedix has a net margin of 45.25% compared to Acumen Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
CorMedix	45.25%	45.57%	24.76%

Acumen Pharmaceuticals has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

CorMedix has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
CorMedix	$311.71M	2.07	$163.05M	$2.13	3.86

Summary

CorMedix beats Acumen Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Climb Bio?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Climb Bio's return on equity of -31.45% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Climb Bio	N/A	-31.45%	-30.39%

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Climb Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Acumen Pharmaceuticals has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

Climb Bio is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 2 articles in the media. Acumen Pharmaceuticals' average media sentiment score of 1.87 equaled Climb Bio'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Climb Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Acumen Pharmaceuticals presently has a consensus target price of $6.67, suggesting a potential upside of 191.12%. Climb Bio has a consensus target price of $20.30, suggesting a potential upside of 94.44%. Given Acumen Pharmaceuticals' higher probable upside, research analysts plainly believe Acumen Pharmaceuticals is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08

Summary

Climb Bio beats Acumen Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Aerovate Therapeutics?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Aerovate Therapeutics' return on equity of -90.19% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

In the previous week, Acumen Pharmaceuticals had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 2 mentions for Acumen Pharmaceuticals and 0 mentions for Aerovate Therapeutics. Acumen Pharmaceuticals' average media sentiment score of 1.87 beat Aerovate Therapeutics' score of 0.67 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Acumen Pharmaceuticals	Very Positive
Aerovate Therapeutics	Positive

Acumen Pharmaceuticals has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 10.2% of Acumen Pharmaceuticals shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Acumen Pharmaceuticals presently has a consensus price target of $6.67, indicating a potential upside of 191.12%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Acumen Pharmaceuticals is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Acumen Pharmaceuticals beats Aerovate Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Acumen Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABOS vs. The Competition

Export

Metric	Acumen Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$171.18M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-1.23	17.78	22.17	24.18
Price / Sales	N/A	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	1.97	6.63	9.84	6.72
Net Income	-$121.33M	$24.20M	$3.57B	$337.19M
7 Day Performance	-9.84%	-4.39%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	114.02%	45.50%	26.49%	33.10%

Acumen Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABOS Acumen Pharmaceuticals	2.6333 of 5 stars	$2.29 -3.4%	$6.67 +191.1%	+120.2%	$171.18M	N/A	N/A	20	Positive News
DSGN Design Therapeutics	2.7635 of 5 stars	$11.08 +1.0%	$16.50 +48.9%	+160.3%	$692.06M	N/A	N/A	40
SLDB Solid Biosciences	2.7936 of 5 stars	$6.81 +2.9%	$16.36 +140.3%	+95.7%	$670.44M	N/A	N/A	100	Analyst Forecast Gap Up
CRMD CorMedix	3.4876 of 5 stars	$8.27 +3.6%	$15.00 +81.4%	-34.7%	$648.78M	$311.71M	3.88	30	Positive News
CLYM Climb Bio	3.3061 of 5 stars	$11.25 +2.3%	$20.30 +80.4%	+709.3%	$644.18M	N/A	N/A	9	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABOS) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. DSGN, SLDB, CRMD, CLYM, and AVTE

How does Acumen Pharmaceuticals compare to Design Therapeutics?

Summary

How does Acumen Pharmaceuticals compare to Solid Biosciences?

Summary

How does Acumen Pharmaceuticals compare to CorMedix?

Summary

How does Acumen Pharmaceuticals compare to Climb Bio?

Summary

How does Acumen Pharmaceuticals compare to Aerovate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. DSGN, SLDB, CRMD, CLYM, and AVTE

How does Acumen Pharmaceuticals compare to Design Therapeutics?

Which has higher valuation and earnings, DSGN or ABOS?

Do analysts rate DSGN or ABOS?

Is DSGN or ABOS more profitable?

Which has more volatility and risk, DSGN or ABOS?

Do insiders and institutionals believe in DSGN or ABOS?

Does the media favor DSGN or ABOS?

Summary

How does Acumen Pharmaceuticals compare to Solid Biosciences?

Which has more volatility & risk, ABOS or SLDB?

Do institutionals and insiders hold more shares of ABOS or SLDB?

Is ABOS or SLDB more profitable?

Do analysts recommend ABOS or SLDB?

Which has preferable valuation and earnings, ABOS or SLDB?

Does the media refer more to ABOS or SLDB?

Summary

How does Acumen Pharmaceuticals compare to CorMedix?

Does the media favor ABOS or CRMD?

Do institutionals and insiders hold more shares of ABOS or CRMD?

Do analysts rate ABOS or CRMD?

Is ABOS or CRMD more profitable?

Which has more risk and volatility, ABOS or CRMD?

Which has stronger earnings and valuation, ABOS or CRMD?

Summary

How does Acumen Pharmaceuticals compare to Climb Bio?

Is ABOS or CLYM more profitable?

Do insiders and institutionals hold more shares of ABOS or CLYM?

Which has more risk & volatility, ABOS or CLYM?

Which has better earnings & valuation, ABOS or CLYM?

Does the media refer more to ABOS or CLYM?

Do analysts rate ABOS or CLYM?

Summary

How does Acumen Pharmaceuticals compare to Aerovate Therapeutics?

Is ABOS or AVTE more profitable?

Which has higher valuation & earnings, ABOS or AVTE?

Does the media favor ABOS or AVTE?

Which has more risk & volatility, ABOS or AVTE?

Do institutionals and insiders believe in ABOS or AVTE?

Do analysts prefer ABOS or AVTE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools